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AIDS 2007, 21:111–122A novel 24-base pair deletion in the coding region of CCR5 in an African populationThe chemokine receptor CCR5 is the main co-receptor
for macrophage-tropic HIV-1 strains, which are respon-
sible for virus transmission and predominate during the
asymptomatic phase of the disease [1]. This has been
demonstrated by the almost complete resistance of
individuals homozygous for a 32-base pair (bp) deletion
in the coding region of the receptor (CCR5D32) [2].
Other natural genetic variants of the CCR5 coding
region or promoter have been described that modulate
HIV-1 disease progression or the function of the receptor
[3].
During a study analysing the influence of genetic host
factors on the risk of vertical transmission of HIV-1
in Kigali, Rwanda, we identified the heterozygous
carriage of a novel 24-bp deletion in the coding region
of CCR5 (denoted hCCR5D24) in an infected mother
and her infected child. In addition, we detected two
subjects heterozygous for hCCR5D24 in a cohort of 36
HIV-1-serodiscordant couples originating from the
same region.
A total of 178 pairs of HIV-1-positive women and
children in Kigali were enrolled in a cohort study for the
prevention of mother-to-child HIV-1 transmission, from
March 2002 to October 2004. Frozen peripheral blood
mononuclear cell pellets were collected and sent to the
Retrovirology Laboratory in Luxembourg for the analysis
of HIV co-receptor polymorphisms, including a stop
codon at amino acid position 101 of CCR5 (mutation
m303 [4]). For the sequencing of samples encoding
hCCR5D24, DNA extracts were amplified using a
nested polymerase chain reaction (PCR) protocol. The
outer PCR was performed using primers 326F
(50–TGCTTGGCCAAAAAGAGAGT–30) and 977R
(50–GATGATTCCTGGGAGAGACG–30) and was
subsequently separated on a 2% agarose gel electropho-
resis. The 24-bp-deleted fragments were gel-purified
using the QiaexII kit (Qiagen, Venlo, The Netherlands)
and an inner PCR was performed using primers 472F
(50–GGTGGAACAAGATGGATTATCAAGAGT–30)
and 882R (50–CAGCATGGACGACAGCCAGG–30).
Sequencing was performed on purified amplicons using
the BigDye terminator cycle-sequencing chemistry (PE
Applied Biosystems, Foster City, California, USA), and
primers 472F and 882R.
Although the screening for the m303 mutation proved
negative for all women and children, we identified anopyright © Lippincott Williams & Wilkins. Unauth
ISSN 0269-9370 Q 2007 Lippincunusual migration pattern on the gel electrophoresis in an
infected mother and her infected child, suggesting the
heterozygous carriage of a large deletion (Fig. 1a). The
screening was extended to a cohort of 36 serodiscordant
couples, and revealed the existence of two unrelated
heterozygotes for hCCR5D24, one infected and one
non-infected. Compared with a reference (GenBank
accession no. U95626), the sequence analysis revealed
a 24-bp deletion from nucleotide 61730 to 61753
(accession no. AY947540), involving eight amino acids
(V83–A90) located in the second transmembrane helix
(Fig. 1b and c).
To date, the most widely studied CCR5 mutation is
CCR5D32, which results in a non-functional protein.
The prevalence of CCR5D32 is extremely low in sub-
Saharan Africa [5,6], so the presence of the 24-bp deletion
in a central African population is remarkable. On the basis
of our observation, the allelic frequency of hCCR5D24
seems rare in Rwanda. However, our study on the genetic
background of CCR5 in Rwanda was restricted to a
selected population. A better evaluation of the prevalence
of hCCR5D24 in Rwanda, and thus of its impact on
HIV-1 transmission and disease progression, should also
rely on other subject categories, for example healthy
uninfected volunteers and larger groups of high-risk
HIV-1-seronegative individuals.
hCCR5D24 is expected to affect the receptor topology
and its functionality as a chemokine receptor or as an
HIV-1 co-receptor, although it does not alter the
reading frame of CCR5. P84, F85 and Y89 are critical
residues for chemokine binding affinity and the
functional activation of CCR5 [7,8]. Impaired HIV-1
co-receptor function is also expected, through structural
constraints in domains critical for binding the gp120
envelope subunit of R5-tropic HIV-1 and for HIV-1
fusion [9–11], or through altered CCR5 expression.
Interestingly, a 24-bp deletion has been found in the
CCR5 of an African simian species (red-capped
mangabeys) [12]. That mutation (D24 CCR5) encom-
passed eight amino acids in frame in the fourth
transmembrane helix. Red-capped mangabeys homo-
zygous for D24 CCR5 were found to be naturally
infected with divergent SIV, which was unable to use
CCR5, but instead used CCR2b as its major co-
receptor. Taken together, these findings support the
likelihood that hCCR5D24 will impair the physiologi-
cal or HIV-related functions of CCR5.orized reproduction of this article is prohibited.
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Fig. 1. Mutational analysis of hCCR5D24. (a) Analysis of CCR5 polymerace chain reaction fragments on a 3% agarose gel: 1.
Smart ladder (Eurogentec, Seraing, Belgium); 2. CCR5WT/CCR5WT; 3. CCR5WT/hCCR5D24; 4. negative control. (b) Nucleotide
sequence of CCR5 surrounding the deleted region, and translation into the normal receptor (top) or the truncated mutant (bottom).
(c) Schematic representation of the CCR5 sequence: ECL, extracellular loop; ICL, intracellular loop; TM, transmembrane helix.
Black circles denote deleted residues in hCCR5D24. The arrow indicates the location of CCR5D32 and grey-shaded circles denote
other known genetic variants of CCR5 [9]. Broken lines depict disulphide bonds linking together CCR5 extracellular domains
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J Exp Med 1998; 188:2057–2065.Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1
receptor inhibitor, in AIDS–Kaposi’s sarcomaThe endothelial proliferation of Kaposi’s sarcoma (KS) is
dependent on vascular endothelial growth factor (VEGF).
Its receptor, Flk-1/KDR, is overexpressed and active
in an autocrine feedback loop [1]. SU5416, a potent
inhibitor of VEGF-mediated Flk-1 receptor signaling,
was tested in patients with a variety of malignancies. As
angiogenesis is rarely found in adult life, inhibition was
anticipated to have little toxicity. Despite a favorable
toxicity profile in earlier trials with nearly 150 patients
and no dose-limiting toxicity in a phase I trial in AIDS–
KS (S. Miles, personal communication), the investigation
of SU5416 in patients with AIDS–KS was halted after
two patients died after developing thrombocytopenia,
renal failure and acidosis.
Patients with biopsy-confirmed, chemotherapy-refrac-
tory or intolerant AIDS–KS, with measurable cutaneous
lesions and adequate hematological, renal and hepatic
function were treated in two parallel studies, one
conducted in the United States by the AIDS Malignancy
Consortium and one in Europe. Eligible patients received
SU5416 145 mg/m2 twice weekly intravenously.Table 1. Concomitant medications.
Case 1 Lamivudine, saquinavir, ritonavir, and stavudine,
trimethoprim/sulfamethoxazole (PCP prophylaxis), and
allopurinol 100 mg daily
Case 2 Ritonavir, amprenavir, saquinavir, stavudine, efavirenz,
abacavir, lamivudine, trimethoprim/sulfamethoxazole
(PCP prophylaxis), celecoxib, primaquine, loperamide,
azithromycin, clotrimazole, clindamycin, calcium salts,
furosemide, bumetanide, phytonadione (vitamin K),
acetaminophen, diphenhydramine, prochlorperazine,
hydromorphone, simethicone, lorazepam, and sodium
polystyrene sulfonate.
PCP, Pneumocystis carinii pneumonia.Case 1
A 58-year-old man with AIDS–KS diagnosed in February
1999, treated with liposomal doxorubicin (17 June to
1 September 1999), received SU5416 from 5 February
to 22 May 2000. Baseline platelet counts and renal
function were normal, the HIV-RNA level was less than
20 copies/ml and the CD4 cell count was 388 cells/ml.
Concomitant medications are shown in Table 1. On
22 May 2000, the patient presented with fatigue, fever, andleg edema. He had ascites, thrombocytopenia (29 000/ml)
without schistocytes, creatinine 1.7 mg/dl, uric acid
14 mg/dl, total bilirubin 1.3 mg/dl, alkaline phosphatase
300m/l, gamma transferase 85m/l. He underwent
hemodialysis and infusion of fresh frozen plasma. On
5 June 2000, the HIV-RNA level was 50 000 copies/ml
and CD4cell count was 109 cells/ml. The patient was taken
off antiretroviral therapy and started on ciprofloxacin
and acyclovir on 6 June 2000. The patient died on
12 June 2000.Case 2
A 48-year-old man was diagnosed with AIDS in
September 1989 and Kaposi’s sarcoma in July 1999,
had been treated previously with liposomal doxorubicin
(24 September 1999 to 14 January 2000) and paclitaxel
(14 February to 19 May 2000), and had received a single
dose of SU5416 on 23 June 2000. Concomitant
medications are shown in Table 1. Baseline laboratoryorized reproduction of this article is prohibited.
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creatinine level of 3.1 on 27 May 2000 for less than 48 h.
On 24 June 2000 he experienced progressive difficulty in
breathing. On 27 June 2000, the patient was dyspneic
(36 breaths/minute) despite good oxygen saturation, clear
lungs and a normal chest X-ray.
On 3 July 2000, the dyspnea persisted without cough,
fever, or chest pain. He had oral thrush, a tender liver and
chronic leg edema. Platelets were 23 000/ml without
schistocytes and he had lactic acidosis. He developed
serosanguinous bilateral pleural effusions with negative
cultures and possible ascites. He was treated empirically
for Pneumocystis carinii pneumonia with clindamycin,
primaquine, and methylprednisolone. The antiretroviral
medications and trimethoprim/sulfamethoxazole were
maintained. The patient received one unit of platelets,
furosemide, and bumetanide. Repeat laboratory findings
were: absolute neutrophil count 1.1, platelets 23 000/ml,
sodium 120 mEq/l, bicarbonate 13 mEq/l and creatinine
3.9 mg/dl. He was persistently febrile with negative
cultures. The patient died on 7 July 2000.
We have described two patients who received SU5416, a
potent inhibitor of VEGF-mediated Flk-1 receptor
signaling, who developed unexpected thrombocytope-
nia, renal failure and death. The exact pathophysiology is
unknown. Autopsies were not performed. The advanced
AIDS, multiple antiretroviral medications, chronic
anemia, and, in the second patient, a previously resolved
and rather brief renal insufficiency, are many variables that
may have interacted.
In the first patient a precipitous increase in HIV viral load
accompanied the hepatorenal failure and thrombo-
cytopenia. In the second patient, abacavir and stavudine
have rare renal toxicity and may have contributed to
acute renal failure and acidosis. Multi-organ thrombosis
including pulmonary embolism may have been the cause
of death given the dyspnea, low-grade fever, and leg
edema. Nonetheless, in neither patient were schisto-
cytes noted, a requisite for a diagnosis of thrombotic
thrombocytopenic purpura. Progressive renal failure
played a role in both cases. The bilateral pleural effusion
and ascites in patient 2 suggested a capillary leak
syndrome. SU5416 administration has also been associ-
ated with a risk of thrombosis when given in combination
with paclitaxel [2].
Before this study, experience with SU5416 in the setting
of HIV infection was limited. Only one of 69 patients
enrolled in other SU5416 phase I protocols had AIDS,
but that patient did not have significant toxicities.
Moreover, although thrombosis was reported in less than
10% of patients in phase II trials of SU5416, no cases of
renal failure or death were reported in 200 patients [3–6].
An expanded safety SU5416 database (n¼ 393) revealed
five previous cases of grade III/IV transient renal failure orpyright © Lippincott Williams & Wilkins. Unauthoracidosis, all related to volume depletion or gentamicin.
However, unique toxicities may occur in the setting of
HIV, contributing to infection and mortality, as seen in a
subset of patients with low CD4 cell counts receiving
combined rituximab and cyclophosphamide–hydroxy-
daunorubicin–vincristine–prednisone chemotherapy
[7]. Similarly, patients with AIDS-associated KS treated
with imatinib had unanticipated diarrhea at doses usually
tolerated in other cancer patients [8]. Finally, taxanes were
associated with increased toxicity in the setting of hepatic
cytochrome CYP3A4 inhibition by the concomitant
administration of azole antifungal agents [9] or delavir-
dine and saquinavir [10]. Taken together, these obser-
vations suggest that patients with HIV infection should be
evaluated separately for toxicity on clinical trials of
investigational agents.
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284.A delayed immune reconstitution inflammatory syndromeFig. 1. Computed tomography scan showing area of con-
solidation with a new cavitation in the right upper lobe.The immune reconstitution inflammatory syndrome
(IRIS) among HIV-infected patients initiating combina-
tion antiretroviral therapy (CART) and pretreated for an
opportunistic infection is commonly described [1–3]. In
the case of HIV patients receiving both antituberculous and
antiretroviral drugs, it seems to be quite a frequent event,
concerning 29–36% of patients [4]. In multivariate
analysis, the independant reported risk factors for IRIS
are disseminated tuberculosis, the timing of the initiation
of CART after tuberculosis treatment, a rapid increase
in CD4 cells or decrease in the viral load greater than
2 log copies/ml under CARTwithin a month [1,5,6]. The
currently admitted physiopathological basis of IRIS is a
sudden CART-mediated increase in antigen-specific cells,
which in turn induces an explosive response against
mycobacterial antigen [3,7]. Usually IRIS occurs when
the delay between antituberculous therapy and CART
initiation is approximately 2 months, with a maximal
reported latency of 40 weeks [8].
We describe here a case of possible IRIS occurring more
than a year and a half after the initiation of anti-
tuberculous treatment.
A 43-year-old Laotian man, seropositive for HIV-1 but
not yet treated, presented with pulmonary tuberculosis
with a large cavity in the right upper lobe in April 2004,
and soon after began his treatment with a combination
including rifampicin, isoniazid, ethambutol and pyrazi-
namid. The absolute number of CD4 cells at the initiation
of antituberculous treatment was 261 cells/ml. The
patient remained contagious for 6 months, as a result
of inadequate drug concentrations. The dosage was
progressively increased, adapted to blood drug concen-
trations, until a dosage corresponding to a weight of 60 kg
was reached, although the patient weighed only 35 kg.
Three other antituberculous drugs were added to avoid
the selection of a resistant strain during the period of
inadequate drug concentration. The last positive culture
of a respiratory specimen was taken in October 2005, and
the strain was still responsive to all drugs.
In August, a pneumothorax was drained in the chest
surgery department. In October, a fistula appeared on the
scarof the drain. This eventwas considered as the first IRIS,
even though the patient was not taking CART, and was
treated successfully with steroids (1 mg/kg) for 2 months.The antituberculous regimen was simplified to rifampicin
and isoniazid in December, after clinical improvement
and 2 months of negative respiratory specimen cultures.
In September 2005, 20 months after antituberculous
therapy initiation, CART was introduced, using an
combination of nucleoside inhibitors and efavirenz. Just
before treatment initiation, the absolute CD4 cell count
was 317 cells/ml, and the viral load was greater than
5.7 log10 copies/ml.
Three weeks after the initiation of CART, at the end of
October, the patient noticed a fistula on the scar of the
chest drain. The absolute CD4 cell count was 422 cells/ml
and the viral load was 2.7 log10 copies/ml. Drug con-
centrations (rifampicin and efavirenz) were within the
therapeutic ranges. All the microbiological specimens
(from the fistula and respiratory tract) were negative for
tuberculosis. A computed tomography scan did not show
any evidence of tuberculosis reactivation. The fistula
disappeared spontaneously in one month, at the end of
November.
The patient was hospitalized in the same period to
explore asthenia, weight loss and a cough lasting for a
month. Semi-invasive aspergillosis was diagnosed in the
sequellar cavity on the basis of microbiological and
radiological findings (see Fig. 1). The specific treatment
was introduced on 9 December and symptoms
progressively disappeared.orized reproduction of this article is prohibited.
Co
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the generally admitted definition [4,6]. It was a
reappearance of a previous tuberculosis manifestation
(fistula), despite effective antituberculous therapy (correct
rifampicin concentration), after the exclusion of a relapse
of tuberculosis or other diagnosis (negative microbiological
examination for both tuberculosis or other microorgan-
isms). It occurred 3 weeks after the initiation of CART,
which delay is similar to those usually reported [4,6,8]. It
also occurred in the context of rapid immune-virological
improvement, 3 weeks after the initiation of CART. A
histological examination of the products of the fistula was
not performed, but could have provided more evidence of
IRIS by showing inflammation mediated by T cells.
This report is unusual in the unusually long delay between
the antituberculous treatment and the initiation of
CART. In the literature, we did not find any report of
such latency between the initiation of antituberculous
treatment and the occurrence of IRIS.
In our case, we could hypothesize that the patient had a
weak specific immune response against tuberculosis,
perhaps constitutional, and was not able to clear the
tuberculous antigens rapidly. He may have also presented
with a primary disseminated tuberculosis. Therefore, it is
possible that tuberculosis antigens remained numerous
even after 20 months of treatment, especially in the
context of an insufficient dosage of antituberculous drugs
during the initial months, leading to an IRIS when
CART was initiated [3].
We also have to bear in mind the diagnosis of IRIS
even after a long time after antituberculous treatment
initiation, to propose therapy based on steroids in the case
of severe symptomatology.
The diagnosis of aspergillosis could also have been
considered as IRIS in this context, as suggested by others
[9], but with the lack of evidence of latent aspergillosis
before CART initiation, it was not possible to validate this
hypothesis. This hypothesis seems interesting, but more
observations need to be gathered. Fungal examinations
should be systematically proposed in these patients withpyright © Lippincott Williams & Wilkins. Unauthorsignificant sequellar cavities of tuberculosis, mainly before
CART initiation.
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on? AIDS 2005; 19:2179–2181.Basal RANTES promoter activity differs considerably among different species of monkeys: implications for
HIV-1/AIDS progressionRegulated upon activation: normal T-cell expressed/
secreted (RANTES) is an important chemokine that
interacts with the chemokine receptor CCR5 (HIV-1
co-receptor). It is important to study the genetic
differences in the promoter region of the RANTES
gene in different species of monkeys because it is used as
an animal model to undestand HIV-1/SIV pathogenesis
and also for vaccine studies. We present varying levels ofbasal promoter activity that may impact the progression of
HIV/SIV.
The chemokine system plays an important role in
modulating viral entry, tropism and pathogenesis [1–3].
Earlier studies had clearly established that b-chemokines
(RANTES, macrophage inflammatory proteins, ligands
for chemokine receptor CCR5) as well as others couldized reproduction of this article is prohibited.
CCorrespondence 117interfere with the interaction of host cells with HIV-1 [3].
The protective effects of IL-4 -589Tand RANTES -28G
on HIV-1 disease progression have recently been reported
[4]. SIV also exploits the chemokine system to infect
certain species of monkeys [2]. Besides, monkeys are used
as an animal model for understanding the pathogenesis of
SIV/HIVand also for AIDS vaccine-related studies. Based
on the species of monkeys used for HIV/SIV challenge,
they produce varying pattern of disease, and the genetic
basis for these differences needs to be studied. With this
aim, we sought to carry out a comparative study on the
basal promoter activity of the RANTES promoter of
several species of monkeys simultaneously on human and
monkey cells. Earlier studies in humans identified two
mutations (28G and 403A) in the cis-acting regions
(promoter) of RANTES that controlled the progression
of HIV-1 [5]. We amplified the promoter region of
RANTES according to the method described earlier by
us [6]. In that communication we reported the presence
of four highly polymorphic regions (A–D) in the
promoter region (spanning þ78 to 413) of several
monkeys. We hypothesized that such changes could
potentially modulate the production of RANTES. The
following primer pairs with Xho1 and HindIII restriction
sites, respectively, were engineered in the beginning of





TAGCAAT–30The sequences underlined represent Xho1 and HindIII
restriction sites. PCR amplified products were cloned
into the PGL3 luciferase reporter vector (Promega
Biotech, Wisconsin, USA). This vector is designed to


















































































Fig. 1. An approximately 604 bp fragment containing the essent
earlier. They were cloned into the PGL3 enhancer containing ve
described in the text and luciferase activity was determined frompromoter.The PCR product (604 bases) was isolated from
the gel using the QIA-quick gel extraction kit (Qiagen,
Hilden, Germany), digested with Xho1 and HindIII and
ligated into the PGL3 vector digested with the same two
restriction enzymes using T4 DNA ligase (Promega).
Equal amounts of Qiagen column purified plasmid DNA
(0.4mg) per 0.1 106 cells in a 12-well plate were
transfected along with an internal control (pSV-b-gal;
Promega), which uniformly gave 70–80% transfection
efficiency. Both human (Magi-CCR5, obtained from the
National Institutes of Health AIDS reagent programme)
and monkey cells (Cos-1) were transfected for 24 h with
lipofectin (Gibco BRL, Eggenstein, Germany), and cell
lysates were prepared for the detection of luciferase
activity using a kit from Promega (luciferase assay system).
Relative luciferase activity obtained with two normal
humans and four species of monkeys are shown in
Fig. 1(a and b). They are mean SD from four different
experiments. Luciferase units were normalized and
compared against the values obtained by transfecting
only the vector PGL3. The pattern of promoter activity
was essentially the same for the two cell lines used. Both
normal humans showed very little basal activity in Cos-1
and human cells. Langur monkeys (Prebytes entellus)
showed approximately twofold more activity in Cos-1
compared with its activity in human cells. Remarkably,
both rhesus (Macaca mulatta) and marmoset (Callith rix
jacchus) monkeys always showed significantly more
promoter activity (approximately fivefold in Cos-1 and
threefold in human cells). In contrast, bonnet monkeys
showed significantly less basal promoter activity in both
cell lines.
We report for the first time variations in the basal
RANTES promoter activity in four commonly used
species of monkeys, and show that they differ quite
significantly from each other. These observations are








































ial RANTES promoter elements was amplified as described
ctor. They were transfected into human and mouse cells as
equivalent amounts of lysates using a kit from Promega.
Co
118 AIDS 2007, Vol 21 No 1shown to modulate the progression of HIV-1. As it is one
of the major chemokines for the CCR5 receptor, it may
also be involved in other immune-mediated disorders/
diseases.Acknowledgement
The authors would like to thank Subeer Majumdar for
providing blood samples from the Primate Research
Center of the National Institute of Immunology, New
Delhi, India.
Vikas Sood, Nidhi Gupta, Vijay Shanker, Aalia S. Bano
and Akhil C. Banerjea, National Institute of Immunol-
ogy, JNU Campus, New Delhi 110067, India.
Sponsorship: Grants received by the Department of
Biotechnology, to the National Institute of Immunol-
ogy, New Delhi, and to A.C.B. are gratefully
acknowledged.pyright © Lippincott Williams & Wilkins. UnauthorReceived: 15 July 2006; accepted: 26 September
2006.References
1. Lusso P. HIV and the chemokine system. EMBO J 2006; 25:447–
456.
2. Edinger AL, Clements EJ, Doms R. Chemokine and orphan
receptors in HIV-2 and SIV tropism and pathogenesis. Virology
1999; 260:211–221.
3. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-
1 coreceptors: roles in viral entry, tropism, and disease. Annu
Rev Immunol 1999; 17:657–700.
4. Wichukchinda N, Nakayama EE, Rojanawiwat A, Pathipvanich
P, Auwanit W, Vongsheree S, et al. Protective effects of IL4-589T
and RANTES-28G on HIV-1 disease progression in infected Thai
females. AIDS 2006; 20:189–198.
5. Liu H, Chao D, Nakayama EE, Taguchi H, Gjoto M, Xin X, et al.
Polymorphism in RANTES chemokine promoter affects progres-
sion. Proc Natl Acad Sci U S A 1999; 96:4581–4585.
6. Ramamoorti N, Goila R, Banerjea AC. Extensive polymorphism
in regulated upon activation: normal T cells expressed/secreted
promoter of bonnet, baboon and rhesus monkeys. AIDS 2000;
14:2401–2403.Caspofungin-resistant oral and esophageal candidiasis in a patient with AIDSOropharyngeal candidiasis caused by Candida albicans is one
of the most common opportunistic infections in patients
with advanced HIV infection [1,2]. Azoles, such as
fluconazole, are commonly used to treat these infections;
however, resistance of C. albicans to azoles is problematical
[2–4]. Treatment options for azole-resistant oral and
esophageal candidiasis remain limited. Caspofungin, an
echinocandin with activity against Candida species target-
ing the synthesis of beta-1, 3-glucan in the fungal cell
wall [5], expands the treatment options for azole-resistant
oral–esophageal candidiasis in patients with AIDS [4,5].
Resistance to caspofungin remains uncommon. A patient
with AIDS and azole-resistant oral–esophageal candidiasis
caused by C. albicans is described who developed clinically
significant resistance to caspofungin despite conflicting
minimum inhibitory concentration (MIC) results.
A 44-year-old man with advanced HIV/AIDS infection
presented with azole-resistant oral–esophageal candidiasis
caused by C. albicans. The patient had previously been
treated sequentially with oral nystatin solution, flucona-
zole, and itraconazole solution without a favorable
response. The patient’s CD4 cell count had been less than
10 cells/ml for more than 4 years, and the viral load was
greater than 100 000 copies/ml. HIV genotyping and
phenotyping showed significant resistance to all three main
classes of antiretroviral agents. Additional co-morbidities
included hepatitis B infection, perianal human papillo-
mavirus infection and squamous cell carcinoma, hyper-
tension, and renal insufficiency (estimated creatinine
clearance 75 ml/min).Caspofungin treatment was begun with a loading dose of
70 mg intravenously once, followed by 50 mg intrave-
nously a day for 14 days. The patient tolerated the
medication well and examination showed marked
clearing of the oral lesions. His appetite improved and
he gained weight. Caspofungin treatment was re-initiated
3 months later as a result of a recurrence of symptoms.
After his second course, he again showed improvement,
which persisted a few months. He subsequently received
five additional 2-week treatment courses, administered
over one year. These treatment courses were periodically
interrupted and prematurely terminated as a result of
missed infusion appointments. The clinical effectiveness
of the medication gradually diminished. After the seventh
and final course of caspofungin, the plaques showed no
change and the patient experienced no clinical improve-
ment. Shortly thereafter the patient moved to a new
geographical area.
Only C. albicans was cultured from oral swabs taken
periodically throughout the patient’s treatment course; all
isolates showed high-level resistance to fluconazole. The
MIC of caspofungin calculated from the first sample
obtained before the initiation of therapy was 0.13mg/ml
or less, comparable to that seen in fluconazole-resistant
and caspofungin-susceptible C. albicans [6]. Susceptibility
testing showed an MIC of 0.03mg/ml after the fourth
course of caspofungin (approximately 11 months after the
first treatment), at which time resistance was clinically
suspected, and an MIC of 1.0mg/ml during the
sixth treatment course, approximately 16 months afterized reproduction of this article is prohibited.
CCorrespondence 119beginning treatment. At both points in time the patient
showed increasing numbers of persistent oral plaques
despite caspofungin treatment, in contrast to his response
during his initial course. After his seventh and final course
of caspofungin, approximately 19 months after his first
course, the MIC was less than 0.03mg/ml.
This patient with AIDS and azole-resistant oral–
esophageal candidiasis demonstrated clinically progressive
resistance to caspofungin, despite conflicting suscepti-
bility results. It is possible, and likely, that this patient’s
treatment interruptions, incomplete treatment courses,
and the prolonged duration of treatment hastened the
onset of treatment failure and clinical resistance. Before
treatment, the caspofungin MIC was low as expected, and
was consistent with that found in C. albicans strains known
to be caspofungin susceptible. Testing performed later
continued to show an unexpectedly low MIC, despite the
fact that the patient showed signs suggestive of treatment
failure. Caspofungin-resistant Candida species typically
have an MIC at least greater than 1.0mg/ml (L.C.
Sadowski, personal communication). Hernandez et al. [7]
described a caspofungin MIC greater than 64mg/ml in
the setting of caspofungin treatment failure in an AIDS
patient with C. albicans esophagitis. Kartonis et al. [8] also
reported no correlation between caspofungin MIC levels
and clinical outcomes in patients with esophageal
candidiasis or invasive candidiasis. Although it is possible
that pharmacokinetic variability was a factor in this
patient, the patient’s initial positive response, the
standardized dosing, and the length of time between
dose administrations suggest that this would be unlikely.
This report highlights the importance of recognizing the
possibilities of clinical resistance of C. albicans to
caspofungin and the lack of a close relationship between
MIC levels and clinical resistance. Genetic and enzymatic
analysis of C. albicans isolates in patients failing
caspofungin treatment could further the understanding
of mechanisms of resistance and susceptibility testingopyright © Lippincott Williams & Wilkins. Unauthmethodologies, and provide new directions for the
development of novel therapies.
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Chemother 2005; 49:3616–3623.Nifedipine–lopinavir/ritonavir severe interaction: a case reportLopinavir is administered co-formulated with a low
ritonavir dose (a potent cytochrome P450(CYP)3A4
inhibitor). As lopinavir is predominantly metabolized via
cytochrome P450(CYP)34A, the subtherapeutic dose of
ritonavir inhibits lopinavir metabolism resulting in higher
lopinavir concentrations, especially higher trough levels
[1,2].
Nifedipine (a dihydropyridine calcium antagonist) is
also a cytochrome P450(CYP)34A substrate [3]. The
co-administration of ritonavir with nifedipine may sig-
nificantly increase serum concentrations of nifedipineresulting in toxicity: headache, peripheral oedema,
hypotension and tachycardia. Although this interaction
has only a theoretical substantiation, it is well described as
a low grade, usually clinically irrelevant interaction [3].
We report a case of a nifedipine– low-dose ritonavir
interaction with severe hypotension and renal failure
confirmed with an unintended re-exposition to the
drugs.
A 47-year-old man was diagnosed with HIV infection in
1992. His medical history included two bouts of
Pneumocystis jiroveci pneumonia, chronic hepatitis C andorized reproduction of this article is prohibited.
Co
120 AIDS 2007, Vol 21 No 1hypertension treated with nifedipine 30 mg/12 h, dox-
azosine 1 mg/12 h and furosemide 40 mg/8 h. HAART
(estavudine 40 mg/12 h, lamivudine 300 mg/24 h and
lopinavir/ritonavir three pills/12 h) was begun in 2002.
In March 2005, hypotension and progressive renal failure
were noted; HAARTwas withdrawn, when the CD4 cell
count was 105 cells/ml, and a kidney biopsy confirmed
membranoproliferative glomerulonephritis.
In May 2005, during his follow-up, lopinavir/ritonavir
re-introduction was decided when he was receiving
nifedipine 30 mg/12 h, doxazosine 1 mg/12 h and fur-
osemide 40 mg/8 h.On the second day the patient
developed malaise, severe hypotension (90/50 mmHg),
oliguria, and progressive generalized oedemas. Serum
creatinine was 5 mg/dl (creatinine before HAART re-
introduction was 1.7 mg/dl). All antihypertensive and
antiretroviral drugs were discontinued, and the patient
was managed with symptomatic treatment and hydro-
electrolitic repletion. Renal function progressively
improved, the creatinine level lowered to 3 mg/dl, the
clinical symptoms vanished and blood pressure normal-
ized. The episode was diagnosed as prerenal acute kidney
failure and antihypertensive drugs were re-introduced
one week later, first nifedipine 30 mg/12 h, and later
enalapril 5 mg/12 h and losartan 50 mg/12 h. At that time
the patient was clinically stable, with good control of
blood pressure and a serum creatinine level of 1.7 mg/dl.
One week later the re-introduction of lopinavir/ritonavir
was decided. Again, after 48 h another hypotension
episode occurred, with malaise, oedemas and renal
insufficiency (creatinine peak 7 mg/dl). Every drug was
stopped and in approximately 72 h a progressive clinical
and biochemical improvement was noted.
As an interaction between HAART and antihypertensive
drugs was suspected, in June 2005 only HAART was re-
introduced. The patient went on improving, reaching a
creatinine level of 2.5 mg/dl. Amlodipine 15 mg/24 h, a
dihydropiridine calcium antagonist metabolized via
CYP314, was substitued for nifedipine. Two week later
the patient was discharged with creatinine 2.8 mg/dl and
a diagnosis of severe hypotension with secondary renal
failure caused by a pharmacologic interaction between
nifedipine and HAART. During a 6-month follow-up
the patient was clinically stable with well-controlled
hypertension and a creatinine level of 2 mg/dl.
We describe a case of acute renal insufficiency with severe
hypotension and oedema caused by a pharmacokinetic
interaction. When nifedipine is administered to a patient
receiving ritonavir, CYP450 is inhibited and this can lead
to a high nifedipine trough level, resulting in hypotension
and renal failure, especially in patients with some degree of
renal insufficiency. Hypotension can induce a quick and
severe renal failure in patients with mild renal insufficiency.pyright © Lippincott Williams & Wilkins. UnauthorAs we could not find a suitable cause for the first
hypotension episode, HAART and antihypertensive
drugs were re-introduced after clinical improvement.
This fuelled another hypotension episode that confirmed
the pharmacokinetic interaction between ritonavir and
nifedipine through an unintended re-exposition. At this
point we decided to associate stavudine, lamivudine and
lopinavir/ritonavir with amlodipine, a drug with a
metabolism not affected by ritonavir [3] and it was
well tolerated.
Pharmacokinetic ritonavir interactions can result in
clinically meaningful problems, at least with ketocona-
zole, itraconazole, amiodarone, quinidine, atovaquone,
nicardipine and methadone. The levels of all those drugs,
and their effects, can be greatly heightened by ritonavir.
As has been shown, a nifedipine–ritonavir interaction can
lead to serious clinical problems. At this time it is not
known whether there is any nifedipine dose that can be
used safely when co-administered with ritonavir. As
lopinavir is available only co-formulated with ritonavir,
it is difficult to ascertain the differential CYP inhibi-
tory effects of lopinavir (if any) and ritonavir in this
interaction. Further research, especially in patients
receiving many drugs and with co-morbidities, is needed
if ritonavir and nifedipine are going to be used together in
the future [4].
To the best of our knowledge, this is the first description
of a severe interaction between nifedipine and ritonavir
leading to prerenal kidney failure induced through severe
hypotension.
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CCorrespondence 121National adult antiretroviral therapy guidelines in S
We read with interest the article by Beck and colleagues
[1] who examined the adult antiretroviral therapy (ART)
guidelines in 43 World Health Organization (WHO) ‘3outh Africa: concordance with 2003 WHO guidelines?by 5’ focus countries. The authors found that the national
guidelines of a majority of countries had a good degree
of concordance with the WHO 2003 guidelines [2].
Although concordance was noted to be inversely related
to health expenditure per capita, the authors did not
further explore the reasons why some countries have
adopted guidelines that differ from the current WHO
recommendations. One such country is South Africa,
which has among the highest per capita income of
countries in subSaharan Africa and also has much better
healthcare infrastructure than most. Despite these
resources, the South African national ART programme
currently bases its treatment guidelines on the former
WHO 2002 guidelines that recommend ART only for
patients with WHO stage 4 disease (AIDS) or a blood
CD4 cell count of less than 200 cells/ml [3]. We believe
these guidelines advocate treatment at too late a stage
of disease and that they represent a compromise that
may substantially undermine the effectiveness of the
programme in the long term.
The key goals of an ART programme are to prevent
morbidity and mortality. We have recently demonstrated
in a historical natural history cohort in Cape Town, South
Africa, that 52% of HIV-associated deaths actually occur
before the development of stage 4 disease [4]. Moreover,
the rate of progression to AIDS among patients with CD4
cell counts of 200–350 cells/ml was almost twice that
reported in natural history cohorts in high-income
countries [4,5]. Therefore, under the current South
African national guidelines, much HIV-associated mor-
bidity and mortality in this setting occurs among patients
before the eligibility for ART.
Data from ART programmes also suggest that treat-
ment is being initiated too late. Within a community-
based programme in Cape Town, the mortality rate
among referred individuals eligible to start ART is
extremely high, exceeding 30 deaths per 100 person-
years [6]. Moreover, during 3 years follow-up of this
cohort, 87% of mortality occurred in the interval just
before treatment initiation or during the first 16 weeks
of ART [7]. Collectively, these data indicate that
patients are arriving with disease that is too far advanced.
More worryingly, these data are likely to be indicative of
a huge burden of mortality occurring upstream of the
ART programme.
South Africa is at the epicentre of the continent’s HIV-
associated tuberculosis epidemic, with tuberculosis
notification rates in many townships reaching almost
unprecedented levels [8]. The extent to which ART may
assist in tuberculosis control at the community level isopyright © Lippincott Williams & Wilkins. Unauthhighly dependent upon how early ART is initiated and
upon the extent to which ART reduces the incidence of
tuberculosis during long-term treatment [9]. Under the
South African ART guidelines, pulmonary tuberculosis
(WHO stage 3 disease) per se is not a criterion for the
consideration of ART. This may well represent a critical
missed opportunity; by the time our patients initiate
ART, 52% of them have already completed treatment for
one or more episodes of tuberculosis and 25% are
receiving treatment for current tuberculosis [10]. The
later the initiation of ART, the greater the burden of
tuberculosis that accrues. Moreover, the long-term
incidence of tuberculosis during ART in this cohort
remains five to 10-fold higher than that among HIV-non-
infected individuals despite excellent virological out-
comes [10]. This is likely to reflect the suboptimal
restoration of tuberculosis-specific immunity, which is a
further factor strongly associated with the late initiation of
ART [11]. In view of these outcomes, the late initiation of
ART could paradoxically undermine tuberculosis control
in South Africa [12].
Clearly, in addition to medical factors, economic and
logistic constraints also affect the ART eligibility criteria
set by different national ART programmes. However,
economic data also indicate the benefits of earlier
treatment. Cost-effectiveness analyses using local data
from Cape Town indicate that it is more cost effective to
treat patients with less advanced disease, although the
overall investment is greater [13,14]. Collectively, these
data point in the same direction, favouring earlier
initiation of ART than is at present recommended in
South Africa. Good medical practice mandates that
treatment guidelines should not be ‘cast in stone’ but
should be continually reviewed and revised in the light of
emerging data. We conclude that the six million people
living with HIV in South Africa might be much better
served by the national ART guidelines being brought up
to date with current revised WHO guidelines. As Beck
and colleagues [1] point out, the WHO guidelines have
been developed so that ‘an effective and appropriate
standard of care can be maintained’.
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